Condensed Consolidated Statements of Operations (Unaudited) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
		Jun. 30, 2021	Jun. 30, 2020	Jun. 30, 2021	Jun. 30, 2020
Net revenues
Total net revenues		$ 2,537	$ 2,266	$ 7,246	$ 3,199
Cost of sales
Total cost of sales		924	882	3,089	1,398
Gross profit		1,613	1,384	4,157	1,801
Operating costs and expenses
Research and development		4,190	3,164	6,621	6,537
General and administrative		4,941	5,211	11,312	15,816
Sales and marketing		1,099	2,024	2,625	5,718
Restructuring and other charges		11	2,084	436	2,536
Total operating costs and expenses		10,241	12,483	20,994	30,607
Operating loss		(8,628)	(11,099)	(16,837)	(28,806)
Other income (expenses)
Gain on extinguishment of debt		3,612		3,612
Change in fair value of common stock warrant liability		1,807	(1,591)	(2,220)	2,941
Inducement loss on sale of liability classified warrants				(5,197)
Interest expense, net		(39)	(65)	(77)	(77)
Other income, net		60	78	121	225
Net loss		$ (3,188)	$ (12,677)	$ (20,598)	$ (25,717)
Net loss per share attributable to common stockholders
Basic		$ (0.04)	$ (0.33)	$ (0.26)	$ (0.72)
Diluted		$ (0.04)	$ (0.33)	$ (0.26)	$ (0.72)
Weighted average shares outstanding
Basic	[1]	80,602,931	38,428,289	78,392,881	35,724,141
Diluted		81,162,256	38,428,289	78,392,881	35,724,141
Product [Member]
Net revenues
Total net revenues		$ 1,195	$ 944	$ 2,924	$ 1,372
Cost of sales
Total cost of sales		207	275	448	615
Service [Member]
Net revenues
Total net revenues		1,342	1,322	4,322	1,827
Cost of sales
Total cost of sales		$ 717	$ 607	$ 2,641	$ 783

[1] In December 2020 and January 2021, the Company sold pre-funded warrants to purchase up to 5,238,043 and 2,420,910 shares of common stock, respectively. The shares of common stock associated with the pre-funded warrants are considered outstanding for the purposes of computing earnings per share prior to exercise because the shares may be issued for little or no consideration, are fully vested, and are exercisable after the original issuance date. The pre-funded warrants sold in December 2020 and January 2021 were exercised during the period and included in the denominator for the period of time the warrants were outstanding.